Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgery PartnersFRA:1SP -2.29%65 EV-to-EBITDA is 13.38 as of Aug. 07, 2026, which is 28% below its 10-year median of 18.61. GuruFocus rates FRA:1SP with a GF Score™ of 65/100 and a GF Value™ of €23.00 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 510 Healthcare Providers & Services companies, Surgery Partners ranks worse than 58.82% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Surgery Partners's enterprise value is €6,569 Mil.
Surgery Partners's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was €491 Mil. Therefore, Surgery Partners's EV-to-EBITDA for today is 13.38.
The historical rank and industry rank for Surgery Partners's EV-to-EBITDA or its related term are showing as below:
FRA:1SP'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.27 Med: 18.61 Max: 45.19
Current: 13.28
During the past 13 years, the highest EV-to-EBITDA of Surgery Partners was 45.19. The lowest was 11.27. And the median was 18.61.
FRA:1SP's EV-to-EBITDA is ranked worse than 58.82% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.92
vs FRA:1SP: 13.28
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Surgery Partners (FRA:1SP) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Surgery Partners's PE Ratio (TTM) for today is calculated as:
Surgery Partners's share price for today is €12.80.
Surgery Partners's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.514.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Surgery Partners's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1SP vs AVAH, ASTH, ADUS: EV-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Surgery Partners's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgery Partners EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgery Partners's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Surgery Partners's EV-to-EBITDA falls into.
Surgery Partners's current Enterprise Value is €6,569 Mil.
Surgery Partners's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €491 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgery Partners (FRA:1SP) has a EV-to-EBITDA of 13.38 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Surgery Partners. This is 28% below median its historical median of 18.61. Over the past decade, Surgery Partners' EV-to-EBITDA has ranged from 11.27 to 45.19. According to the industry distribution chart, Surgery Partners ranks #300 out of 510 companies in the Healthcare Providers & Services industry, placing it in the top 58.8%.
Is Surgery Partners' EV-to-EBITDA too high?
Surgery Partners' current EV-to-EBITDA of 13.38 is 28% below median its 10-year median of 18.61. Over the past 10 years, this metric has ranged from a low of 11.27 to a high of 45.19. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.92. Surgery Partners' value of 13.38 is 22.5% above this industry median. Based on the distribution chart, Surgery Partners ranks #300 out of 510 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Surgery Partners has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Surgery Partners' EV-to-EBITDA compare to AVAH and ASTH?
According to the Healthcare Providers & Services industry distribution chart, Surgery Partners ranks #300 out of 510 companies for EV-to-EBITDA. This places Surgery Partners in the lower half of its industry. The industry median EV-to-EBITDA is 10.92. Surgery Partners' value of 13.38 is 22.5% above this benchmark. Historically, Surgery Partners' own EV-to-EBITDA has ranged from 11.27 to 45.19 over the past decade. While the company's 10-year median is 18.61 vs. the industry median of 10.92, Surgery Partners has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.92, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgery Partners's current EV-to-EBITDA of 13.38 is 22.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Surgery Partners. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgery Partners's current EV-to-EBITDA is 13.38, which is 28% below median its own 10-year median of 18.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgery Partners stock overvalued right now?
Based on GuruFocus' analysis, Surgery Partners (FRA:1SP) is currently considered Possible Value Trap. The stock's GF Value™ is €23.00, compared to a current price of €12.80 — trading 44.3% below its estimated fair value. The current EV-to-EBITDA is 13.38, which is 28% below median its 10-year median of 18.61 and 22.5% above the Healthcare Providers & Services industry median of 10.92. Surgery Partners' overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Surgery Partners (FRA:1SP), the current EV-to-EBITDA is 13.38 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgery Partners (FRA:1SP) Overvalued in 2026?
Based on GuruFocus' analysis, Surgery Partners stock appears to be undervalued.
The current stock price of €12.80 is trading 44.3% below its estimated GF Value™ of €23.00.
GuruFocus considers Surgery Partners to be Possible Value Trap.
Key valuation signals for FRA:1SP:
EV-to-EBITDA: 13.38 (28% below median its 10-year median of 18.61)
GF Value™: €23.00 vs. price of €12.80 (44.3% below fair value)
Industry Position: 22.5% above the Healthcare Providers & Services median (#300 of 510)
No single metric tells the full story. See the FRA:1SP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgery Partners Inc is a healthcare services company with an integrated outpatient delivery model focused on providing quality, cost-effective solutions for surgical and related ancillary care in support of both patients and physicians. It has one reportable segment: Surgical Facilities, which includes the operation of ASCs, surgical hospitals, anesthesia services, and multi-specialty physician practices, which earn revenues from contracts with patients in which the performance obligations are to provide health care services.
65GF Score
Get the complete analysis for FRA:1SP
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SP has been successfully added to your 
